Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 14/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845152 | 0.84 | ADRA1A (0.56) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845167 | 0.82 | ADRA1A (0.54) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845151 | 0.82 | ADRA1A (0.54) | ADRA1ARECQLL3MBTL3L3MBTL1 | |
| SCHEMBL16845155 | 0.81 | ADRA1A (0.56) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845111 | 0.80 | ADRA1A (0.61) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845199 | 0.80 | ADRA1A (0.64) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845181 | 0.79 | ADRA1A (0.48) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845201 | 0.78 | ADRA1A (0.51) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL16845086 | 0.78 | ADRA1A (0.59) | ADRA1AL3MBTL3L3MBTL1MBTD1TP53BP1 | |
| Trifluoroacetic Acid SCHEMBL18185568 | 0.78 | ADRA1A (0.50) | ADRA1AL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| WO-2015091415-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | ADRA1A 1241/4885RECQL 1117/4885L3MBTL3 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.